The biggest development for Hospira was a $15 billion takeover bid from pharmaceuticals giant Pfizer. The deal, which at press time was being evaluated by anti-trust regulators in Europe, is expected to close by the end of 2015. Hospira continued to be dogged by problems with its infusion pumps, despite the lifting of an FDA-imposed import ban on producgts made in a Costa Rica plant. The FDA warned hospitals about a security risk with 2 models. The vulnerability, discovered by security researcher Billy Rios, could allow hackers to upload a new drug library into Hospira’s remotely-programmed LifeCare PCA3 and PCA5 devices, creating a risk for potentially deadly doses of anesthetic or pain drugs.